CPhI Annual Reports - how accurate were they 5 years on?

27 Jul 2017

The CPhI predictions foresaw advancement in QbD, continuous processing, and a dramatic rise in FDA warning letters.

CPhI Worldwide, organized by UBM, announces the 2017 expert panel for the highly anticipated CPhI Worldwide Annual Industry Report (5th edition), which will be released in two parts - part one in late summer and part two during CPhI Worldwide (24-26 October 2017 in Frankfurt). The report is a comprehensive and critically important publication that analyses key trends and innovations forecast by a panel of world-class experts.

CPhI Annual Reports - how accurate were they 5 years on?

Since this is the 5th edition, CPhI Worldwide has decided to look back at previous Annual Reports to see how accurate the predictions were. These included the expanded use of PAT, QbD, serialization, green chemistry and R&D improvements, as well as the rise of strategic relationships between pharma and CMOs (or CDMOs as they are now called). However, a potential hindrance to the industry was the predicted rise in the number of FDA warning letters.

The 2013 Annual Report forewarned of the rapid increase of FDA warning letters as a result of a tightening regulation environment and a lagging industry. This prediction proved entirely accurate with FDA warning letters tripling over the past few years, from 4882 in 2012 to 14,590 in 2016. Another bold prediction from the first report was an expected boom in pharmaceutical R&D and improvements in development cycles. Interestingly, this was true in 2014 and 2015, stellar years for New Molecular Entities (NMEs)) and Biologics License Applications (BLAs), with 41 and 45 FDA approvals, respectively. This increased productivity, however, dropped off significantly in the following years, with 22 in 2016 and a similar number anticipated for 2017.

As predicted, PAT, QbD and serialization have now become industry-wide practices that further ensure quality and efficiency. Another trend identified, is the implementation of continuous processing in both Big Pharma and CDMOs for APIs and finished products, and the use of these technologies is now increasing. In addition, both pharma and outsourcing providers were correctly anticipated by the reports to begin looking at green chemistry, route scouting and process improvements earlier in development to make less wasteful products and this has already begun taking shape across the industry.

CMOs were anticipated to grow in prominence across the industry, with strategic pharma partnerships proliferating. In the past 2 years, mega-mergers were expected to become more frequent amid the aggressive competition to become leading and full service providers. This is perhaps best highlighted by the recent deals struck between a number of CDMOs and pharma companies, as well as the purchase of Patheon by Thermo Fisher. In addition, Big Pharma has also set-up co-development deals with a number of companies, particularly to develop and commercialise biologics and biosimilars.

However, some of the first Annual Reports missed the pulse of the industry, expecting tighter regulations to have a consequential effect of decreasing the number of biotechs and small companies entering the market. In contrast, the biotech environment has significantly heated up in last couple of years, with the traditional hot spots in the US seeing growth as well as a rapid emergence of newer biotech hubs – particularly in China.

This year’s CPhI Annual Report features 12 experts that provide valuable insight on the current and future state of our industry, including manufacturing, R&D, regulations, biologics, PAT/QbD, and innovation, among many others.

The CPhI Expert Panel members for 2017 are
  • · Gil Roth, President at the PBOA
  • · Alan Sheppard, Principal, Global Generics at IMS Health
  • · Vivek Sharma, CEO at Piramal Enterprises Ltd
  • · Ajaz Hussain, Founder CEO at Insight Advice & Solutions LLC
  • · Dr Minzhang Chen, CEO at STA Pharmaceutica
  • · Dilip Shah, CEO at Vision Consulting Group
  • · Prabir Basu, Pharma Manufacturing and Regulations Consultant
  • · Brian Carlin, Global Excipients Expert
  • · Emil Cuirczak, President at Doramaxx Consulting
  • · Bikash Chatterjee, President and CSO at PharmTech Associates
  • · Girish Malhotra, President at EPCOT Internationa
  • l
  • · B.S.V. Prasad, Senior Vice-President and Head of Small Molecules Business Unit at Biocon Ltd
  • “This year’s Annual Report features some of the industry’s most stellar names and pharmaceutical industry experts and we are extremely grateful for all their efforts. It is a testament to their work and industry acumen that so many of their foresights 5 years on are beginning to take shape across industry. It also adds to the growing weight of evidence that the CPhI Annual Report is an essential document for anyone looking to stay ahead of market trends, explore new partnerships, opportunities and technologies, and to ultimately help advance the industry more quickly,” commented Orhan Caglayan, Brand Director – Europe, UBM.

    Read More

    Related news

    Third Sartorius Research Xchange Forum 2019 focuses on CAR-T cell therapy

    Third Sartorius Research Xchange Forum 2019 focuses on CAR-T cell therapy

    13 Mar 2019

    Event for experts from academia and industry, including talks, live demo sessions, and panel discussion.

    Read more 
    Overcoming lyophilization challenges at Interphex 2019

    Overcoming lyophilization challenges at Interphex 2019

    10 Mar 2019

    Line of Sight approach to freeze-drying enables organizations to bring pharmaceutical products safely and quickly to market.

    Read more 
    'Tamper-evident' benefits are evident

    'Tamper-evident' benefits are evident

    28 Feb 2019

    2019 will mark Uniplast's debut at this year's edition of CPhI Worlwide in Frankfurt, where it will showcase its expertise in plastic packaging.

    Read more 
    Japan solid dose market predicted to bloom in 2019

    Japan solid dose market predicted to bloom in 2019

    21 Feb 2019

    Executives predict Japan to be the second fastest growing mature market for solid dose drugs in 2019, and the second fastest overall country for biologicals growth.

    Read more 
    Pharma in South East Asia booming as CPhI opens event for the first time in Thailand

    Pharma in South East Asia booming as CPhI opens event for the first time in Thailand

    27 Feb 2019

    Healthcare and pharmaceutical reforms, designed to increase access to high-value medicines, driving growth.

    Read more 
    Pharmapack Europe 2019 Award Winners

    Pharmapack Europe 2019 Award Winners

    7 Feb 2019

    Awards showcased a wide range of industry-changing discoveries in drug delivery, packaging and automation.

    Read more 
    Pharmapack report predicts diversification of innovation leading to a rise in licensing and partnering

    Pharmapack report predicts diversification of innovation leading to a rise in licensing and partnering

    27 Jan 2019

    New report highlights Germany, France and Switzerland as tier-one nations for ‘drug delivery innovation’, and warns the challenge will be to scale-up and approve promising prototypes.

    Read more 
    Fiera Milano to host CPhI Worldwide 2020

    Fiera Milano to host CPhI Worldwide 2020

    20 Jan 2019

    The exhibition district will see the world's largest pharma industry event.

    Read more 
    BASF’s new active ingredients target skin conditions’ root causes

    BASF’s new active ingredients target skin conditions’ root causes

    15 Jan 2019

    New active ingredients coming from the research of BASF’s innovation platforms on epigenetics, microbiome and extraction.

    Read more 
    Future-oriented packaging concepts from Sanner

    Future-oriented packaging concepts from Sanner

    11 Dec 2018

    Company will showcase a range of packaging solutions, from desiccant and customized packaging to smart packaging solutions, at Pharmapack.

    Read more